MorphoSys Announces Three New Clinical Milestones
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Three New Clinical Milestones
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Three Partners Bring HuCAL Antibodies into Clinical Trials: All Six Partnered
Clinical Milestones Expected for 2010 Achieved
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
three of its partners have filed applications for phase 1 clinical trials with
HuCAL antibodies. In each case, the filing of the application triggers an
undisclosed milestone payment to MorphoSys. The therapeutic antibodies are being
developed in the therapeutic areas of cancer and inflammatory diseases. Today's
announcement brings to six the number of HuCAL antibodies that have entered
clinical development in 2010. Details on the individual programs will be
published as the respective trials commence.
"This has been an outstanding year for progress in our pipeline," commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "The number of
partnered HuCAL antibody programs in the clinic has almost doubled - from seven
at the end of last year to 13 now. With the three new starts announced today,
seven different partners from the pharmaceutical and biotechnology industry are
currently running clinical trials with our antibodies. Milestone payments from
these programs are an important source of revenue for MorphoSys. Even more
importantly, we are building substantial long-term value for the company as
programs advance into and through clinical development."
With today's news, a total of six HuCAL-derived antibodies have advanced into
human clinical trials in 2010: the three announced today together with two
programs from the alliance with Novartis and one from Centocor Ortho Biotech. As
a result, MorphoSys's clinical pipeline currently comprises eight partnered
programs in Phase 1 and five in Phase 2 development as well as the Company's
proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid
arthritis, and MOR208, which is in a Phase 1 trial for cancer.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
?
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered
trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release (PDF):
http://hugin.info/130295/R/1471133/407968.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1471133]
Unternehmensinformation / Kurzprofil:
Datum: 10.12.2010 - 07:03 Uhr
Sprache: Deutsch
News-ID 49588
Anzahl Zeichen: 6214
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 369 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Three New Clinical Milestones"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
